Skip Navigation

Nephrology Dialysis Transplantation 2007 22(6):1505-1507; doi:10.1093/ndt/gfm217
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in NDT
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Cunningham, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cunningham, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Bisphosphonates in the renal patient

John Cunningham

The Royal Free Hospital – Centre for Nephrology, Pond St London NW3 2PF, UK

Correspondence and offprint requests to: John Cunningham, The Royal Free Hospital – Centre for Nephrology, Pond St London NW3 2PF, UK. Email: drjohncunningham@aol.com

Keywords: bisphosphonates; Bone; CKD

The first 10% of the full text of this article appears below.

Over the past decade, bisphosphonate use in patients with various forms of kidney disease has become widespread. The extensive take up-of these agents by nephrologists reflects the twin perceptions that bisphosphonates are generally safe in patients with kidney disease, and that skeletal protection, readily demonstrable in bisphosphonate-treated populations without kidney disease, is also achievable in patients with chronic kidney disease (CKD) and other forms of nephropathy. Unfortunately, both of these perceptions are based on limited evidence and somewhat tenuous extrapolations [1,2].



   The case for bisphosphonates in patients with renal disease
 
In the non-renal population, convincing evidence exists to show that bisphosphonates can effectively prevent, or at least attenuate, bone loss in glucocorticoid-treated patients [3–8]. There is evidence of significant fracture reduction in this patient group. Benefit is also seen in glucocorticoid-treated patients with normal or near normal renal function and inflammatory disease [5]. It was reasonable, therefore, . . . [Full Text of this Article]



   Safety
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in NDT:

Effect of risedronate on high-dose corticosteroid-induced bone loss in patients with glomerular disease
Yuichi Kikuchi, Toshihiko Imakiire, Muneharu Yamada, Takamitsu Saigusa, Toshitake Hyodo, Taketoshi Kushiyama, Keishi Higashi, Naomi Hyodo, Kojiro Yamamoto, Shigenobu Suzuki, and Soichiro Miura
NDT 2007 22: 1593-1600. [Abstract] [FREE Full Text]  

Risedronate, an effective treatment for glucocorticoid-induced bone loss in CKD patients with or without concomitant active vitamin D (PRIUS-CKD)
Naohiko Fujii, Takayuki Hamano, Satoshi Mikami, Yasuyuki Nagasawa, Yoshitaka Isaka, Toshiki Moriyama, Masaru Horio, Enyu Imai, Masatsugu Hori, and Takahito Ito
NDT 2007 22: 1601-1607. [Abstract] [FREE Full Text]  

In this issue ...

NDT 2007 22: i. [Extract] [FREE Full Text]  



This article has been cited by other articles:


Home page
 CJASNHome page
N. D. Toussaint, G. J. Elder, and P. G. Kerr
Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue
Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 221 - 233.
[Abstract] [Full Text] [PDF]